Dogwood Hits Key Milestone in Chemotherapy Pain Trial — Dogwood Therapeutics, Inc.

Event summary

Dogwood Therapeutics enrolled the first 200 patients in its Phase 2b HAL-CINP trial for Halneuron®, treating chemotherapy-induced neuropathy.
Top-line data from the four-week study is expected in fall 2026.
Interim analysis showed pain improvement separation from placebo with a low 4.5% dropout rate.
Halneuron® is a non-opioid NaV 1.7 analgesic with FDA fast track designation for CINP treatment.

The big picture

Dogwood's progress in the HAL-CINP trial positions it as a key player in developing non-opioid solutions for chemotherapy-induced pain, an area with significant unmet medical need. The company's focus on voltage-gated sodium channel modulation and LRP1 agonism represents innovative approaches to neuropathic pain management. With CK Life Sciences as its largest shareholder, Dogwood has substantial backing to advance its pipeline through critical clinical stages.

What we're watching

Clinical Efficacy: Whether Halneuron® can sustain pain improvement separation from placebo through final data readout.
Regulatory Pathway: The pace at which FDA fast track designation could accelerate Halneuron®'s approval process.
Pipeline Progress: How SP16 IV's fully funded Phase 1b trial will impact Dogwood's neuropathy treatment portfolio.